DBV Technologies SA – (NASDAQ:DBVT)’s share price traded up 3.7% during mid-day trading on Tuesday . The company traded as high as $35.35 and last traded at $35.07, with a volume of 65,772 shares changing hands. The stock had previously closed at $33.83.

A number of equities analysts have issued reports on the stock. Zacks Investment Research raised shares of DBV Technologies SA – from a “sell” rating to a “hold” rating in a research note on Monday, April 18th. Jefferies Group reaffirmed a “buy” rating on shares of DBV Technologies SA – in a research note on Wednesday, June 8th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $50.52.

The company has a 50 day moving average price of $33.59 and a 200 day moving average price of $31.23. The company’s market cap is $1.60 billion.

Other institutional investors recently added to or reduced their stakes in the company. New York State Common Retirement Fund bought a new position in DBV Technologies SA – during the fourth quarter worth about $2,551,000. Jennison Associates LLC boosted its position in DBV Technologies SA – by 0.9% in the fourth quarter. Jennison Associates LLC now owns 721,775 shares of the company’s stock worth $26,208,000 after buying an additional 6,578 shares in the last quarter. Finally, RS Investment Management Co. LLC raised its stake in DBV Technologies SA – by 1.7% in the fourth quarter. RS Investment Management Co. LLC now owns 502,860 shares of the company’s stock worth $18,259,000 after buying an additional 8,220 shares during the last quarter.

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.